Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Debt (2018 - 2025)

Historic Total Debt for Akebia Therapeutics (AKBA) over the last 8 years, with Q3 2025 value amounting to $47.6 million.

  • Akebia Therapeutics' Total Debt rose 2421.07% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 2421.07%. This contributed to the annual value of $38.7 million for FY2024, which is 1156.19% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Total Debt of $47.6 million as of Q3 2025, which was up 2421.07% from $47.1 million recorded in Q2 2025.
  • Akebia Therapeutics' Total Debt's 5-year high stood at $98.2 million during Q2 2022, with a 5-year trough of $30.1 million in Q1 2024.
  • Moreover, its 5-year median value for Total Debt was $47.6 million (2025), whereas its average is $61.7 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Total Debt crashed by 5671.67% in 2023, and later surged by 5429.09% in 2025.
  • Akebia Therapeutics' Total Debt (Quarter) stood at $97.5 million in 2021, then plummeted by 32.26% to $66.1 million in 2022, then tumbled by 47.51% to $34.7 million in 2023, then rose by 11.56% to $38.7 million in 2024, then grew by 23.13% to $47.6 million in 2025.
  • Its last three reported values are $47.6 million in Q3 2025, $47.1 million for Q2 2025, and $46.5 million during Q1 2025.